Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reward Circuit Abnormalities in Depression and Dopamine Pathway Regulation
NCT03148509Phase 4Unknown
- Sponsor
- Peking University
- Start
- Jun 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 4 trial of bupropion, risperidone and aripiprazole in major depressive disorder (MDD) (3 arms), sponsored by Peking University. Primary endpoint: Hamilton Rating Scale for Depression at 8 weeks. Status: unknown.
02
Drugs
bupropionrisperidonearipiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03148509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03148509.